Management of HIV infection can now rely on new classes of antiretroviral drugs (CCR5 antagonists, integrase inhibitors,fusion inhibitors) which represent innovative options compared to the three main drug classes targeting HIV protease or reverse transcriptase (PI, NRTI, NNRTI). Although there is evidence that these new antiretroviral drugs can be effective and relatively safe in patients resistant to the other anti-HIV drugs who have limited treatment options, available data have only been collected for a short period of time and within controlled trials.Thus, collecting long-term safety and efficacy information as well as patient-reported outcomes in a setting of clinical practice is a necessary step to better define the profile of these drugs.
ISS-NIA ITALIAN COHORT: NEW ANTI-HIV INHIBITORS IN PATIENTS EXPERIENCED TO IP, NRTI, NNRTI / Bucciardini, R; Floridia, M; Weimer L., E; Fragola, V; Massella, M; Baroncelli, S; Pirillo, Mf; Galluzzo, Cm; Donnini, S; Mirra, M; Di Gregorio, M; Lucattini, S; Fucili, L; Baldelli, F; Francisci, D; Martinelli, L; Bastianelli, S; Pastore, G; Ladisa, N; Volpe, A; Vullo, V; D'Ettore, G; Ceccarelli, G; Andreoni, M; Sarmati, L; Delle Rose, D; Montano, M; Tozzi, V; Libertone, R; Pucillo, L; Narciso, P; Bellagamba, R; Tommasi, C; Petrosillo, N; Cicalini, S; Sighinolfi, L; Segala, D; Armignacco, O; Preziosi, R; Ferrari, C; Antoni, A; Cavalli, A; Parruti, G; Sozio, F; Cosentino, L; Dionisio, D; Vivarelli, A; Manconi, Pe; Ortu, F; Di Martino, Ml; Chiodo, F; Biagelti, C; Borderi, M; Boni, P; Del Gobbo, R; Paggi, A; Silvestri, C; Scalise, G; Giacometti, A; Cirioni, O; Mura, Ms; Mannazzu, M; Coinu, G; Bellissima, P; Bonfante, S; Neri, D; Guaraldi, Giovanni; Beghetto, Barbara. - In: INFECTION. - ISSN 0300-8126. - STAMPA. - 37:(2009), pp. 63-64. (Intervento presentato al convegno Italian Conference on AIDS and Retroviruses (ICAR) tenutosi a Milano nel 24-26 May 2009).
ISS-NIA ITALIAN COHORT: NEW ANTI-HIV INHIBITORS IN PATIENTS EXPERIENCED TO IP, NRTI, NNRTI.
GUARALDI, Giovanni;BEGHETTO, Barbara
2009
Abstract
Management of HIV infection can now rely on new classes of antiretroviral drugs (CCR5 antagonists, integrase inhibitors,fusion inhibitors) which represent innovative options compared to the three main drug classes targeting HIV protease or reverse transcriptase (PI, NRTI, NNRTI). Although there is evidence that these new antiretroviral drugs can be effective and relatively safe in patients resistant to the other anti-HIV drugs who have limited treatment options, available data have only been collected for a short period of time and within controlled trials.Thus, collecting long-term safety and efficacy information as well as patient-reported outcomes in a setting of clinical practice is a necessary step to better define the profile of these drugs.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
